INFO & CONTACTS:  +39 02 2390 1

A Randomized, Double-blinded, Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression

Phase: Phase III clinical trials

Principal Investigator: Dott. Lo Russo Giuseppe

Main Facility: Oncologia Medica Toraco-Polmonare

Drug: Ivonescimab (SMT112)

Pathologies: Lung cancer

ClinicalTrials.gov: Read the details about clinical trials

This is a global Phase 3 clinical trial designed to evaluate the safety and efficacy of a new investigational immunotherapy, ivonescimab, compared with pembrolizumab, the current standard first-line treatment for this patient population.

The study is intended for patients with metastatic non-small cell lung cancer (NSCLC) who have not previously received systemic therapy for metastatic disease, whose tumors demonstrate high PD-L1 expression, and who do not harbor activating genetic mutations. Participants will be randomly assigned (1:1 randomization) to one of two treatment arms to directly compare the investigational drug with the current standard therapy.

Arm A (Investigational Arm): ivonescimab administered as monotherapy, a novel immunotherapeutic antibody designed to enhance the body's immune response against cancer through a dual mechanism of action.

Arm B (Control Arm): pembrolizumab administered as monotherapy, which represents the current standard first-line treatment for patients with metastatic NSCLC and high PD-L1 expression.

Last update: 16/07/2026

Subscribe to the newsletter

Sign up for our newsletter to stay informed about news, events, and updates from the Institute

Subscribe